NCT00813046View on ClinicalTrials.gov

Safety and Tolerance Study of Grass Pollen-derived Peptides to Treat Allergic Rhinitis

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

December 31, 2008

Primary Completion Date

January 31, 2009

Study Completion Date

January 31, 2009

Conditions
Seasonal Allergic Rhinoconjunctivitis
Interventions
BIOLOGICAL

gpASIT+TM

oral administration of entero-coated capsules containing increasing doses of gpASIT+TM (25 to 1600µg), one dose per day for 4 days

Trial Locations (1)

9000

Hospital University Ghent, Ghent

Sponsors

Lead Sponsor

BioTech Tools S.A.
All Listed Sponsors
lead

BioTech Tools S.A.

INDUSTRY